References
- Cancer in Norway 2007. Cancer incidence, mortality, survival and prevalence in Norway. Cancer registry of Norway 2008.
- Zincke H, Oesterling JE, Blute ML, Bergstrahl EJ, Myers RP, Barrett DM. Long- (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152:1850–7.
- Pound CR, Partin AW, Epstein JI Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395–406.
- Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer Control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528–34.
- Djavan B, Moul JW, Zlotta A, Remzi M, Ravery V. PSA progression following radical prostatectomy and radiation therapy: new standards in the new millennium. Eur Urol 2003;43:12–27.
- Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:995–1000.
- Lerner SE, Blute ML, Bergstrahl EJ, Bostwick DG, Eickholt JT, Zincke H. Analyses of risk factors for progression in patients with pathologically confirmed prostate cancers after radical retropubic prostatectomy. J Urol 1996;156:137–43.
- Mellinger GT, Gleason DF, Bailar J. The histology and prognosis of prostatic cancer. J Urol 1967;97:331–5.
- Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125–8.
- Gleason DF, Mellinger GT, Veterans Administration Cooperative Urologic Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58–64.
- Epstein JI, Allsbrook WCJR, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostate Carcinoma. Am J Surg Pathol 2005;29:1228–42.
- van Oort IM, Schout BM, Kiemeney LA, Hulsbergen CA, Witjes JA. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ confined prostate cancer? Eur Urol 2005;48:572–6.
- Sim HG, Telesca D, Culp SH, Ellis WJ, Lange PH, True LD, Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence. J Urol 2008;179:1775–9.
- Hattab EM, Koch MO, Eble JN, Lin H, Cheng L. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma. J Urol 2006;175:1695–9.
- Mosse CA, Magi-Galluzzi C, Tsuzuki T, Epstein JL. The prognostic significance of tertiary Gleason pattern 5 in radical prostatectomy specimens. Am J Surg Pathol 2004;28:394–8.
- Pan CC, Potter SR, Partin AW, Epstein JL. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Pathol 2000;24:563–9.
- Ohori M, Wheeler TN, Scardino PT. The New American Joint Committee on Cancer and International Union Against Cancer. TNM classification of prostate cancer. Clinicopathologic correlations. Cancer 1994;74:104–14.
- Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23:273–9.
- Aihara M, Wheeler TM, Ohori M, Scardino PT. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology 1994;43:60–6.
- Whittemore DE, Hick EJ, Carter MR, Moul JW, Miranda-Sousa AJ, Sexton WJ. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. J Urol 2008;179:516–22; discussion 522.
- Isbarn H, Ahyai SA, Chun FKH, Budäus L, Schlomm T, Salomon G, Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. Eur Urol 2009;55:394–403.
- Rasiah KK, Stricker PD, Haynes AM, Delprado W, Turner JJ, Golovsky D, Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer 2003;98:2560–5.